194 related articles for article (PubMed ID: 38796440)
1. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
4. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
Kim YG; Byun J; Yoon D; Jeon JY; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
J Diabetes Res; 2016; 2016():1423191. PubMed ID: 28119930
[No Abstract] [Full Text] [Related]
5. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
[TBL] [Abstract][Full Text] [Related]
6. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Liu X; Men P; Wang B; Cai G; Zhao Z
Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
8. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
9. Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
Wei X; Bai Y; Wang Z; Zheng X; Jin Z; Liu X
Diabetol Metab Syndr; 2021 Aug; 13(1):88. PubMed ID: 34446063
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Zhang S; Han X; Ji L
Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
[TBL] [Abstract][Full Text] [Related]
11. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.
Li Z; Lin C; Zhou J; Cai X; Zhu X; Hu S; Lv F; Yang W; Ji L
Expert Opin Investig Drugs; 2022 Sep; 31(9):957-964. PubMed ID: 35968648
[TBL] [Abstract][Full Text] [Related]
14. Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus.
Mu L; Wang Z; Ren J; Xiong X; Jin Z; Liu X
Diabetol Metab Syndr; 2022 Feb; 14(1):30. PubMed ID: 35164839
[TBL] [Abstract][Full Text] [Related]
15. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study.
Esposito K; Longo M; Maiorino MI; Petrizzo M; Gicchino M; Bellastella G; Giugliano D
Diabetes Res Clin Pract; 2019 Sep; 155():107787. PubMed ID: 31326454
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis.
Huang L; Zhong W; Liang X; Wang H; Fu SE; Luo Z
J Clin Densitom; 2024; 27(1):101455. PubMed ID: 38101289
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
19. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
